Interview with Marco Roque, President & CEO of Cassiar Gold Corp.

Our previous interview: https://www.cruxinvestor.com/posts/cassiar-gold-corp-tsxvgldc-whoever-comes-in-on-cassiar-is-going-to-make-a-lot-of-money-9480

Recording date: 17th March 2026

Cassiar Gold Corp. (TSXV:GLDC) operates an advanced exploration project in northern British Columbia with a resource base and infrastructure profile that management believes the market has significantly mispriced. The company controls 2.3 million ounces at its Taurus deposit, comprising 1.9 million inferred ounces at 0.95 grams per tonne and 410,000 indicated ounces at 1.43 grams per tonne. With 91% of these ounces within 150 meters of surface and the deposit remaining open in all directions, the geological foundation provides both near-term development potential and longer-term expansion opportunity.

What distinguishes Cassiar from typical exploration companies is its existing infrastructure position. The property holds valid mine permits, a permitted 300 ton-per-day mill, paved road access, grid power, 25 kilometers of underground workings, and 160 kilometers of access roads. President and CEO Marco Roque emphasizes that these pre-existing assets represent hundreds of millions in sunk capital that competing projects would need to spend and years of permitting timeline already completed.

Despite these advantages, Cassiar trades at approximately $32 Canadian per ounce of enterprise value with an $80 million market capitalization, well below the $50-900 per ounce range management cites for comparable peers. The company's strategic positioning centers on dual development optionality: high-grade underground veins averaging 10-20 grams per tonne capable of generating 30,000-60,000 ounces annually with minimal capital requirements estimated at $3 million Canadian, alongside longer-term open-pit development of the bulk tonnage deposit.

The critical path to production involves re-permitting tailings facilities to current British Columbia standards, estimated at 1.5-2 years, though direct shipping ore arrangements could compress this timeline by 25-33%. With current gold prices creating potential margins exceeding $5,000 per ounce on high-grade material versus $200-300 margins in previous years, management believes the risk-reward profile for near-term development has fundamentally improved, driving increasing strategic interest and supporting the company's transition from exploration toward production.

Learn more: https://www.cruxinvestor.com/companies/cassiar-gold

Sign up for Crux Investor: https://cruxinvestor.com

Interview with Richard Drechsler, President & CEO of Trifecta Gold

Recording date: 17th March 2026

Trifecta Gold is positioning itself as the next potential discovery story in Yukon's Tombstone Gold Belt, where exploration companies have identified over 20 million ounces of new gold resources since 2020. Led by CEO Richard Drechsler, a 20-year Yukon exploration veteran, the company is systematically exploring reduced intrusion-related gold systems in a geological corridor that has transformed Snowline Gold from a penny stock into a multi-billion dollar company.

The company's corporate structure reflects strong institutional backing. Three cornerstone investors control 40% of outstanding shares: Condire Investors holds 20%, Crescat Capital 10%, and an HNW investor group another 10%. Management owns approximately 11% with no seed stock dilution, ensuring alignment with shareholders. All positions were acquired through private placements or market purchases, with the initial 2024 round priced at 15 cents.

Trifecta's inaugural 2025 drilling program at the Rye project delivered encouraging results. Six holes systematically tested different geological environments around a target intrusion located 14 kilometers from the North Canol Road. The first hole intersected 37 meters of over one gram per ton gold, while another hole encountered 1,400 grams per ton silver over two meters. Core samples showed vein densities comparable to or exceeding those at Banyan Gold's successful project, with the correct gold-bismuth-tellurium metal signature present in over 90% of samples.

The technical team brings targeted expertise. Moira Smith, who co-authored papers on intrusion-related systems and worked at Alaska's Pogo deposit, joined the advisory committee alongside Fred Graybeal, former ASARCO chief geologist. The company benefits from logistical support through Archer, Cathro & Associates, which has explored Yukon since 1965.

With $3 million in treasury, including $2 million in flow-through funds, Trifecta plans to mobilize in June for a July-September drilling campaign at Rye. Results are expected from September through year-end. Beyond Rye, the company controls nine additional untested properties in the belt, providing multiple discovery opportunities as it pursues what Drechsler describes as "front end of that LAN curve" value creation.

View Trifecta Gold's company profile: https://www.cruxinvestor.com/companies/trifecta-gold

Sign up for Crux Investor: https://cruxinvestor.com

Interview with Dr. Mark Williams, President & CSO, and J. Roderick Matheson, Director & CEO of Marvel Bioscience Corp.

Recording date: 16th March 2026

Marvel Biosciences is advancing MB-204, a first-in-class treatment for social withdrawal conditions across autism spectrum disorder, depression, and Alzheimer's disease. The clinical-stage biotechnology company targets an underserved therapeutic area affecting millions globally, with autism prevalence reaching one in 36 children in the United States and depression impacting one in eight adults currently on antidepressants. The addressable market spans hundreds of billions of dollars in healthcare costs and lost productivity.

The compound is based on a modified version of an approved Parkinson's medication, providing an established safety foundation for clinical development. Preclinical data demonstrates rapid symptom reversal within one hour of oral dosing in animal models. In head-to-head comparisons, MB-204 outperformed trofinetide, the only FDA-approved Rett syndrome treatment, across all measured behavioral endpoints. Critically, animals treated with MB-204 maintained improvements for two to three weeks after treatment cessation, suggesting semi-permanent neurological changes, while trofinetide benefits disappeared immediately upon stopping.

Marvel's clinical strategy prioritizes orphan disease indications, specifically Rett syndrome and Fragile X syndrome, where Phase 3 success rates exceed 50% due to genetically homogeneous patient populations and validated regulatory pathways. The company has completed manufacturing of clinical-grade material and toxicology studies, positioning MB-204 for immediate Phase 1 entry in Australia within six to twelve months. The Australian regulatory environment offers efficient processes and a 43% research tax credit that significantly reduces development costs.

Marvel holds composition of matter patents in China and Japan, with additional jurisdictions pending. The company has engaged in preliminary partnership discussions, aligning with neuroscience sector dynamics where approximately 70% of companies complete licensing or acquisition deals before Phase 2. Historical precedents show neuroscience acquisitions typically occur at valuations exceeding $80 million at this stage. Trading at $9 million CAD market capitalization, Marvel represents a significant discount to comparable Phase 1 neuroscience firms, with several peers valued between $100-400 million.

Sign up for Crux Investor: https://cruxinvestor.com